Table 3 Changes in HIT-6 headache disability categories after three and six erenumab treatments
From: A prospective real-world analysis of erenumab in refractory chronic migraine
Baseline (N = 162) N (%) | Month 3 (N = 100) N (%) | Month 6 (N = 73) N (%) | |
|---|---|---|---|
Severe impact (60–78) | 156 (96%) | 68 (68%) | 43 (59%) |
Substantial impact (56–59) | 5 (3%) | 3 (3%) | 14 (19%) |
Some impact (50–55) | 1 (1%) | 15 (15%) | 11 (16%) |
Little or no impact (< 48) | 0 (0%) | 14 (14%) | 5 (6%) |